“Hepalink will accelerate the realization of its strategy in the global macromolecule biopharmaceutical space. Cytovance will have the resources to expand its manufacturing capabilities, enhancing its ability in late stage clinical drug production and commercial business,” Li Li, Hepalink’s chairman and CEO, said in a statement.

http://www.genengnews.com/gen-news-highlights/hepalink-usa-to-buy-cytovance-biologics-for-205-68m/81251657/

Of courseit says..."macro"molecule, so I don't know whether that automatically excludes apelbetalone....I'll leave that to the more scientific minded.